Daniel Cattran
Overview
Explore the profile of Daniel Cattran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1926
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barratt J, Liew A, Yeo S, Fernstrom A, Barbour S, Sperati C, et al.
Clin J Am Soc Nephrol
. 2024 Jan;
19(4):452-462.
PMID: 38214599
Background: IgA nephropathy is the most common primary GN. Clinical features of IgA nephropathy include proteinuria, which is the strongest known surrogate of progression to kidney failure. Complement pathway activation...
2.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, et al.
Kidney Int
. 2022 Oct;
103(2):391-402.
PMID: 36270561
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase 2b NEFIGAN trial. To verify...
3.
Krissberg J, OShaughnessy M, Smith A, Helmuth M, Almaani S, Aviles D, et al.
Am J Kidney Dis
. 2022 Oct;
81(3):318-328.e1.
PMID: 36191724
Rationale & Objective: The effects of race, ethnicity, socioeconomic status (SES), and disease severity on acute care utilization in patients with glomerular disease are unknown. Study Design: Prospective cohort study....
4.
Lv J, Wong M, Hladunewich M, Jha V, Hooi L, Monaghan H, et al.
JAMA
. 2022 May;
327(19):1888-1898.
PMID: 35579642
Importance: The effect of glucocorticoids on major kidney outcomes and adverse events in IgA nephropathy has been uncertain. Objective: To evaluate the efficacy and adverse effects of methylprednisolone in patients...
5.
Wong M, Lv J, Hladunewich M, Jha V, Hooi L, Monaghan H, et al.
Am J Nephrol
. 2021 Nov;
52(10-11):827-836.
PMID: 34731857
Introduction: Despite optimal current care, up to 30% of individuals suffering from immunoglobulin A nephropathy (IgAN) will develop kidney failure requiring dialysis or kidney transplantation. The Therapeutic Evaluation of STeroids...
6.
Krissberg J, Helmuth M, Almaani S, Cai Y, Cattran D, Chatterjee D, et al.
Glomerular Dis
. 2021 Nov;
1(3):105-117.
PMID: 34723246
Introduction: Disparities in health-related quality of life (HRQOL) have been inadequately studied in patients with glomerular disease. The aim of this study was to identify relationships between race/ethnicity, socioeconomic status,...
7.
Shulman C, Liang E, Kamura M, Udwan K, Yao T, Cattran D, et al.
Kidney Med
. 2021 Apr;
3(2):257-266.
PMID: 33851121
Rationale & Objective: Pathogenic variants in type IV collagen have been reported to account for a significant proportion of chronic kidney disease. Accordingly, genetic testing is increasingly used to diagnose...
8.
Shah P, Brady T, Meyers K, OShaughnessy M, Gibson K, Srivastava T, et al.
Nephron
. 2021 Mar;
145(3):245-255.
PMID: 33677435
Background/aims: Obesity is a known risk factor for cardiovascular disease and contributes to the development and progression of kidney disease. However, the specific influence of obesity on outcomes in primary...
9.
Canney M, Barbour S, Zheng Y, Coppo R, Zhang H, Liu Z, et al.
J Am Soc Nephrol
. 2021 Jan;
32(2):436-447.
PMID: 33514642
Background: On the basis of findings of observational studies and a meta-analysis, proteinuria reduction has been proposed as a surrogate outcome in IgA nephropathy. How long a reduction in proteinuria...
10.
Barratt J, Rovin B, Cattran D, Floege J, Lafayette R, Tesar V, et al.
Kidney Int Rep
. 2020 Oct;
5(10):1620-1624.
PMID: 33102954
No abstract available.